DSIP: Delta Sleep-Inducing Peptide

What DSIP is

DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide — a short chain of nine amino acids with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It is classified as a neuromodulator, not a classic sedative: rather than forcing sedation, it appears to influence the natural regulation of sleep and several physiological systems.

It is an investigational compound. It is not approved by the FDA or any regulatory agency for human use, and most of the literature comes from preclinical studies and a small number of older human studies. What follows describes published findings for educational purposes.

Discovery (Schoenenberger–Monnier, 1977)

DSIP was isolated in 1977 by Guido Schoenenberger and Marcel Monnier. The finding came from an elegant experiment: the researchers took cerebral venous blood from rabbits while the animals were in slow-wave (delta) sleep and found that this blood, when transferred, could promote the same sleep pattern in other animals.

From that fraction they isolated the responsible peptide and named it for its observed effect on the delta waves of the electroencephalogram. It is one of the first endogenous "sleep factors" to be characterized at the molecular level.

Mechanism & systems it modulates

DSIP's mechanism remains poorly characterized. No single receptor responsible for its effects has been identified; instead, it appears to interact with multiple systems at once. It can cross the blood-brain barrier, which is consistent with a central action. The research areas group as follows:

Sleep and slow waves

The effect that gave it its name: modulation of slow-wave (delta) sleep. The hypothesis is that DSIP acts on sleep architecture — its organization into phases — rather than simply "knocking out" the nervous system as a hypnotic would. This conceptually distinguishes it from classic sedatives.

HPA axis, cortisol and ACTH

One of the most studied lines is stress resilience. DSIP appears to modulate the hypothalamic-pituitary-adrenal (HPA) axis, with reported effects on cortisol and ACTH levels. This connects sleep and stress within a single regulatory axis.

Antinociception and antioxidant

The preclinical literature also describes possible antinociceptive (analgesic) and antioxidant effects, as well as a role in thermoregulation. These are research findings, not established applications.

What the evidence says

The evidence on DSIP is limited and heterogeneous. Most of it comes from preclinical (animal) studies and a small set of older human studies, many with small samples. There is no robust body of modern, controlled clinical trials supporting defined applications.

• The mechanism is not fully elucidated; even which of its effects is primary is debated.
• Results on sleep have been variable across studies.
• Signals on stress/HPA, antinociception and antioxidation are preliminary.

In short: DSIP is an investigational peptide that is interesting for its history and biology, but its efficacy and safety profile in humans is not established. Any use is strictly for research purposes.

Reconstitution

DSIP is supplied as a lyophilized powder in a 10 mg vial and is reconstituted with your own bacteriostatic water at the concentration you define.

Calculation example (10 mg vial + 2 mL bacteriostatic water = 5 mg/mL): to research 0.5 mg → 0.1 mL → 10 units on a U100 syringe.

Refrigerate (2–8 °C) after reconstitution and protect from light. For custom calculations use the reconstitution calculator or see the complete reconstitution guide.

DSIP at Renova

DSIP is available in a 10 mg presentation as lyophilized powder at $135.

Our material is manufactured in a cGMP-compliant US lab that we work with directly, with a Certificate of Analysis (COA) by HPLC and mass spectrometry.